Latest News for: cel

Edit

ASBH – Appointment of CEL (AS Bryden & Sons Holdings Ltd)

Public Technologies 29 Apr 2026
). The text version of this document is not available ... Attachments Original document Permalink.
Edit

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without

Enid News & Eagle 28 Apr 2026
(Nasdaq.
Edit

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Hastings Tribune 28 Apr 2026
Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry ... .
Edit

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Hastings Tribune 28 Apr 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr 28, 2026-- ... .
Edit

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

Enid News & Eagle 28 Apr 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr 28, 2026-- ... .
Edit

GILEAD SCIENCES COMPLETES ACQUISITION OF ARCELLX AHEAD OF POTENTIAL COMMERCIAL LAUNCH OF ANITO-CEL (Form 8-K) (Gilead Sciences Inc)

Public Technologies 28 Apr 2026
GILEAD SCIENCES COMPLETES ACQUISITION OF ARCELLX AHEAD OF POTENTIAL COMMERCIAL LAUNCH OF ANITO-CEL ... The CVR is payable upon achievement of cumulative global net sales of anito-cel of at least $6.0 billion from launch through the end of 2029.
Edit

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with ...

Nasdaq Globe Newswire 27 Apr 2026
CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell ...
Edit

Delaying Amendment to Registration Statement (Form DEL AM) (CEL-SCI Corporation)

Public Technologies 24 Apr 2026
). CEL-SCI CORPORATION. 8229 Boone Blvd. #802. Vienna, Virginia 22182. (703) 506-9460 ... Re.. CEL-SCI Corporation ... CEL-SCI CORPORATION ... CEL-SCI Corporation published this content on April 24, 2026, and is solely responsible for the information contained herein.
Edit

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome

Caledonian Record 22 Apr 2026
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS ....
Edit

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, ...

Nasdaq Globe Newswire 22 Apr 2026
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS ... .
Edit

Miv-cel (Mivocabtagene Autoleucel; ​KYV-101), CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8)​ (Kyverna Therapeutics Inc)

Public Technologies 22 Apr 2026
). The text version of this document is not available ... Attachments Permalink. Disclaimer.
Edit

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting (Form 8-K) (Kyverna Therapeutics Inc)

Public Technologies 22 Apr 2026
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting.
Edit

Design of Phase 3 of KYSA-6, a Global, Open-Label, Randomized, Controlled Study of Miv-cel (Mivocabtagene Autoleucel; KYV-101), a Fully Human CD19 Chimeric Antigen Receptor T-Cell Therapy, Versus Ongoing Standard-of-Care Immunotherapy in Generalized Myasthenia Gravis (Kyverna Therapeutics Inc)

Public Technologies 22 Apr 2026
Miv-cel is a novel therapy with the potential to change the treatment paradigm through deep B-cell depletion and ... More than 100 patients dosed with miv-cel across multiple indications10 ... Miv-cel ... Miv-cel ... Insert miv-cel CAR gene.
Edit

Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting (Kyverna Therapeutics Inc)

Public Technologies 22 Apr 2026
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies - outcomes not previously observed in SPS ... Further, miv-cel was well-tolerated.
Edit

UC, USJ-R reach semis in CEL Season 4 Valorant tilt

The Philadelphia Inquirer 21 Apr 2026
The University of Cebu (UC) Main Webmasters and the University of San Jose-Recoletos (USJ-R) Adelante Jaguars punched their tickets to the lower bracket semifinals... .

Article Search

tools
×
×
×
×